ERBB2 and esophageal adenocarcinoma: The phase 3 CheckMate 649 trial evaluated nivolumab plus chemotherapy versus chemotherapy alone as first‐line treatment for advanced HER2‐negative gastric/GEJ/esophageal adenocarcinoma.